The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services

Yesenia Aponte-Melendez, Pedro Mateu-Gelabert, Chunki Fong, Benjamin Eckhardt, Shashi Kapadia, Kristen Marks, Yesenia Aponte-Melendez, Pedro Mateu-Gelabert, Chunki Fong, Benjamin Eckhardt, Shashi Kapadia, Kristen Marks

Abstract

Background: While people who inject drugs (PWID) are vulnerable to the adverse outcomes of events like COVID-19, little is known regarding the impact of the current pandemic on PWID. We examine how COVID-19 has affected PWID in New York City across four domains: substance use, risk behaviors, mental health, and service utilization.

Methods: As part of a randomized trial to improve access to HCV treatment for PWID, we recruited 165 participants. Eligibility criteria included detectable HCV RNA and recent drug injection. The present cross-sectional analysis is based on a subsample of 106 participants. We compared responses between two separate samples: 60 participants interviewed prior to the pandemic (pre-COVID-19 sample) and 46 participants interviewed during the pandemic (COVID-19 sample). We also assessed differences by study group [accessible care (AC) and usual care (UC)].

Results: Compared to the pre-COVID-19 sample, those interviewed during COVID-19 reported higher levels of mental health issues, syringe reuse, and alcohol consumption and greater reductions in syringe-service programs and buprenorphine utilization. In the analysis conducted by study group, the UC group reported significantly higher injection risk behaviors and lower access to buprenorphine treatment during COVID-19, while during the same period, the AC group reported lower levels of substance use and injection risk behaviors.

Conclusion: The current study provides insight on how COVID-19 has negatively affected PWID. Placing dispensing machines of harm-reduction supplies in communities where PWID live and increasing secondary exchange, mobile services, and mail delivery of supplies may help maintain access to lifesaving supplies during big events, such as COVID-19. Trial registration ClinicalTrials.gov NCT03214679. Registered July 11 2017. https://ichgcp.net/clinical-trials-registry/NCT03214679 .

Keywords: Big events; COVID-19; HCV; New York City; People who inject drugs.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

References

    1. Collyer S, Huq S, Washington K, Wimer C. Spotlight on COVID-19. (2020). Accessed 1 Feb 2021.
    1. Parker K, Minkin R, Bennet J. Economic fallout from COVID-19 continues to hit low er-income Americans hardest. (2020). Accessed 1 Feb 2021.
    1. Rozenfeld Y, Beam J, Maier H, Haggerson W, Boudreau K, Carlson J, Medows R. A model of disparities: risk factors associated with COVID-19 infection. Int J Equity Health. 2020;19(1):1.
    1. Saladino V, Algeri D, Auriemma V. The psychological and social impact of Covid-19: new perspectives of well-being. Front Psychol. 2020;2(11):2550.
    1. Centers for Disease Control and Prevention. COVID Data Tracker. . Accessed 20 May 2021.
    1. Johns Hopkins University and Medicine. . Accessed 1 Jun 2021.
    1. Dumas TM, Ellis W, Litt DM. What does adolescent substance use look like during the COVID-19 pandemic? Examining changes in frequency, social contexts, and pandemic-related predictors. J Adolesc Health. 2020;67(3):354–361.
    1. Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, Ryan J, Hall M, Ezard N, Haber P, Lintzeris N. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):1–7.
    1. Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24(9):2466–2468.
    1. Khatri UG, Perrone J. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 2020;14:e6–e7.
    1. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817–823.
    1. National Institute on Drug Abuse. New Evidence on Substance Use Disorders and COVID-19 Susceptibility. (2020). Accessed 29 Apr 2021.
    1. Substance Abuse and Mental Health Services Administration. (n.d.). Double Jeopardy: COVID-19 and Behavioral Health Disparities for Black and Latino Communities in the U.S. (Submitted by OBHE). (2020). Accessed 29 Apr 2021.
    1. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–39.
    1. Grebely J, Cerdá M, Rhodes T. COVID-19 and the health of people who use drugs: What is and what could be? Int J Drug Policy. 2020;83:102958.
    1. Abadie R, Gelpi-Acosta C, Aquino-Ruiz F, Aponte-Melendez Y. COVID-19 risks among people who inject drugs in Puerto Rico. Int J Drug Policy. 2021;93:102903.
    1. Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020;23(7):e25583.
    1. Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, Morris M. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health. 2021;6:e309–e323.
    1. Islam MM, Topp L, Day CA, Dawson A, Conigrave KM. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int J Drug Policy. 2012;23(2):94–102.
    1. Jemberie WB, Williams JS, Eriksson M, Grönlund AS, Ng N, Blom Nilsson M, Padyab M, Priest KC, Sandlund M, Snellman F, McCarty D, Lundgren LM. Substance use disorders and COVID-19: multi-faceted problems which require multi-pronged solutions. Front Psychiatry. 2020;11:714.
    1. Fong C, Mateu-Gelabert P, Ciervo C, Eckhardt B, Aponte-Melendez Y, Kapadia S, Marks K. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug and Alcohol Depend. 2021;221:108589.
    1. Centers for Disease Control and Prevention. Suspected Nonfatal Drug Overdoses during COVID-19. . (2020). Accessed 20 May 2021.
    1. New York City Department of Health. Consistent with nationwide trends, overdose deaths rise in New York City in First Quarter of 2020. (2020). Accessed 29 Apr 2021.
    1. Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. on 2021 (2020). Accessed 10 Jan 2021.
    1. Kesten JM, Holland A, Linton MJ, Family H, Scott J, Horwood J, Hickman M, Telfer M, Ayres R, Hussey D, Wilkinson J. Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): a qualitative study of experiences of COVID-19 among people who inject drugs. Int J Drug Policy. 2021;98:103391.
    1. Picchio CA, Valencia J, Doran J, Swan T, Pastor M, Martró E, Colom J, Lazarus JV. The impact of the COVID-19 pandemic on harm reduction services in Spain. Harm Reduct J. 2020;17(1):87.
    1. Canadian Centre on Substance Use and Addiction. Impacts of the COVID-19 pandemic on people who use substances: what we heard. 2020.
    1. Munro A, Booth H, Gray NM, Love J, Mohan AR, Tang J, MacGillivray S. Understanding the impacts of novel coronavirus outbreaks on people who use drugs: a systematic review to inform practice and drug policy responses to COVID-19. Int J Environ Res Public Health. 2021;18(16):8470.
    1. Whitfield M, Reed H, Webster J, Hope V. The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. Int J Drug Policy. 2020;83:102851.
    1. Parkes T, Carver H, Masterton W, Falzon D, Dumbrell J, Grant S, Wilson I. ‘They already operated like it was a crisis, because it always has been a crisis’: a qualitative exploration of the response of one homeless service in Scotland to the COVID-19 pandemic. Harm Reduct J. 2021;18(1):1–16.
    1. Malczewski A, Kidawa M, Bevz M. The impact of the COVID-19 epidemic on drug services, drug users and drug market in Poland—findings of the rapid situation assessment. Reitox National Focal Point National Bureau for Drug Prevention, Poland. 2020.
    1. Gelpí-Acosta C, Oyola-Santiago T. Dispatches from Rebellious Colonial Subjects: Harm reduction activism to humanize and support people who inject drugs in Puerto Rico and the New York City Puerto Rican diaspora charts a long and unfinished history. It is a story of half victories and, above all, interminable struggles. NACLA Rep Am. 2020;52(3):252–259.
    1. Friedman SR, Rossi D, Braine N. Theorizing, “Big Events” as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20(3):283–291.
    1. Pouget ER, Sandoval M, Nikolopoulos GK, Friedman SR. Immediate impact of Hurriane Sandy on people who inject drugs in New York City. Subst Use Misuse. 2015;50(7):878–884.
    1. Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, Makarenko I, Larney S. A rapid review of the impacts of "Big Events" on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. Int J Drug Policy. 2021;92:103127.
    1. Vetter S, Rossegger A, Rossler W, Bisson JI, Endrass J. Exposure to the tsunami disaster, PTSD symptoms and increased substance use—an Internet based survey of male and female residents of Switzerland. BMC Public Health. 2008;8(1):1–6.
    1. New York State Executive Chamber. Declaring a Disaster Emergency in the State of New York. (2020). Accessed 5 Jan 2021.
    1. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.
    1. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):17.
    1. Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int J Drug Policy. 2015;26(10):976–983.
    1. McClure B, Mendoza S, Duncan L, Rotrosen J, Hansen H. Effects of regulation on methadone and buprenorphine provision in the wake of Hurricane Sandy. J Urban Health. 2014;91(5):999–1008.
    1. Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276.
    1. New York City Department of Health. Health Department rolls out methadone delivery program for New Yorkers impacted by COVID-19. (2020). Accessed 29 Apr 2021.
    1. Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Substance Abuse. 2021;1–7
    1. Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Subst Abuse Treat. 2022;132:108514.
    1. Davis CS, Samuels EA. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy. 2021;93:102905.
    1. Samuels EA, Clark SA, Wunsch C, Keeler LA, Reddy N, Vanjani R, Wightman RS. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020;14:e8–e9.
    1. Elmer T, Mepham K, Stadtfeld C. Students under lockdown: Comparisons of students’ social networks and mental health before and during the COVID-19 crisis in Switzerland. PLoS ONE. 2020;15(7):e0236337.
    1. Fegert JM, Vitiello B, Plener PL, Clemens V. Challenges and burden of the Coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: a narrative review to highlight clinical and research needs in the acute phase and the long return to normality. Child Adolesc Psychiatry Ment Health. 2020;14:1–1.
    1. Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic—United States, August 2020–February 2021. Morb Mortal Wkly Rep. 2021;70(13):490.
    1. Henry BF, Mandavia AD, Paschen-Wolff MM, Hunt T, Humensky JL, Wu E, Pincus HA, Nunes EV, Levin FR, El-Bassel N. COVID-19, mental health, and opioid use disorder: Old and new public health crises intertwine. Psychol Trauma Theory Res Pract Policy. 2020;12(S1):S111.
    1. Durkheim E. Suicide: a study in sociology. New York: The Free Press; 1951.
    1. Hay B, Henderson C, Maltby J, Canales JJ. Influence of peer-based needle exchange programs on mental health status in people who inject drugs: a nationwide New Zealand study. Front Psych. 2017;7:211.
    1. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–S11.
    1. Adams RE, Boscarino JA, Galea S. Alcohol use, mental health status and psychological well-being 2 years after the World Trade Center attacks in New York City. Am J Drug Alcohol Abuse. 2006;32(2):203–224.
    1. Cerdá M, Tracy M, Galea S. A prospective population based study of changes in alcohol use and binge drinking after a mass traumatic event. Drug Alcohol Depend. 2011;115(1–2):1–8.
    1. Kessler RC, Galea S, Jones RT, Parker HA. Mental illness and suicidality after Hurricane Katrina. Bull World Health Organ. 2006;84:930–939.
    1. Nithke JP, Forbes PA, Ali N, Cutler J, Apps MA, Lockwood PL, Lamm C. Resilience during uncertainty? Greater social connectedness during COVID-19 lockdown is associated with reduced distress and fatigue. Br J Health Psychol. 2021;26(2):553–569.
    1. Radfar SR, De Jong CA, Farhoudian A, Ebrahimi M, Rafei P, Vahidi M, Yunesian M, Kouimtsidis C, Arunogiri S, Massah O, Deylamizadeh A. Reorganization of substance use treatment and harm reduction services during the COVID-19 pandemic: a global survey. Front Psych. 2021;29(12):349.
    1. Wilkinson R, Hines L, Holland A, Mandal S, Phipps E. Rapid evidence review of harm reduction interventions and messaging for people who inject drugs during pandemic events: implications for the ongoing COVID-19 response. Harm Reduct J. 2020;17(1):1.
    1. Seaman A, Leichtling G, Stack E, Gray M, Pope J, Larsen JE, Leahy JM, Gelberg L, Korthuis PT. Harm reduction and adaptations among PWUD in rural Oregon during COVID-19. AIDS Behav. 2021;25(5):1331–1339.
    1. French R, Favaro J, Aronowitz SV. A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic. Int J Drug Policy. 2021;94:103199.
    1. Tringale R, Subica AM. COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange. J Subst Abuse Treat. 2021;121:108181.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다